Although NAT10 knockdown inactivated the PI3K-AKT pathway and inhibited CRC progression to some extent, Remodelin treatment alone induced only reversible growth arrest in CRC cells and demonstrated limited therapeutic efficacy. The gene discussed is AKT1; the disease is colorectal carcinoma.